[现代生物标志物在评估慢性心力衰竭患者发生室性心律失常和心源性猝死风险中的应用可能性]
[Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure].
作者信息
Gasparyan A Zh, Shlevkov N B, Skvortsov A A
机构信息
Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation.
出版信息
Kardiologiia. 2020 Mar 27;60(4):101-108. doi: 10.18087/cardio.2020.4.n487.
Current biomarkers allow diagnosing a wide array of pathological processes and evaluating effects of therapies and prognosis for cardiological patients. This review focuses on a possibility of using N-terminal pro-brain natriuretic peptide (NT-proBNP), soluble suppressor of tumorigenicity 2 (sST2), galectin-3, and other biomarkers in patients with chronic heart failure for evaluating the risk of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
目前的生物标志物可用于诊断多种病理过程，并评估心脏病患者的治疗效果和预后。本综述重点关注在慢性心力衰竭患者中使用N末端脑钠肽前体（NT-proBNP）、可溶性肿瘤抑制因子2（sST2）、半乳糖凝集素-3及其他生物标志物来评估危及生命的室性快速心律失常和心源性猝死风险的可能性。
Zotero 插件